StreetInsider.com News Articles

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Strem Brian M.

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728909.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Strem Brian M.

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728909.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Tosca Melissa

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728920.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Tosca Melissa

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728920.html

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Thu, 02 Jul 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

Presentation Details

Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Thu, 02 Jul 2026 07:00:00 -0400

Presentation Details

About Kiora Pharmaceuticals

Kiora Pharmaceuticals reports KIO-300 reduced seizure activity in lab model

Thu, 18 Jun 2026 07:03:18 -0400

Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data showing that its ion channel modulator KIO-300 suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. The findings were presented at the Epilepsy Foundation Pipeline Conference on June 18, 2026, in Leesburg, Virginia.

In the study, KIO-300 produced sustained suppression of epileptiform activity in hippocampal CA1 slices taken from mice with induced temporal lobe epilepsy. Treatment reduced spontaneous epileptiform event frequency compared with vehicle controls, with statistically significant inhibition beginning 42 minutes after treatment (p < 0.0001). Analysis of cumulative epileptiform burden also showed a significant reduction following KIO-300 exposure (p

Kiora Pharmaceuticals reports KIO-300 reduced seizure activity in lab model

Thu, 18 Jun 2026 07:03:18 -0400

Form 8-K KIORA PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260618/26662699.html

Form 8-K KIORA PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260618/26662699.html

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Thu, 18 Jun 2026 07:00:00 -0400

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.

"These data

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Thu, 18 Jun 2026 07:00:00 -0400

"These data

Form 4 KIORA PHARMACEUTICALS For: Jun 10 Filed by: Walters-Hoffert Lisa